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Highlights 
 HbbTh3/+ mouse is a good model of severe thalassaemia for in-utero therapy  
 Better  chimerism  after  in-utero  and  postnatal  transplantation  with 
immunosuppression  
 In-utero  gene  therapy  produced  partial  haematological  correction  but  not  
full rescue  
 Both  strategies  need  further  optimisation  to  overcome  hostile 
microenvironment  
Abstract 
Major haemoglobinopathies place tremendous strain on global resources. Intrauterine 
haemopoietic cell (IUHCT) and gene (IUGT) therapies can potentially reduce perinatal 
morbidities with greater efficacy than postnatal therapy alone. We performed both 
procedures in the thalassaemic HbbTh3/+ murine model. Intraperitoneal delivery of 
coisogenic cells at E13-14 produced dose-dependent chimerism. High-dose adult bone 
marrow (BM) cells maintained 0.2-3.1% chimerism over ~24 weeks and treated 
heterozygotes demonstrated higher chimerism than wild-type pups (1.6 vs. 0.7%). Fetal liver 
cells produced higher chimerism compared to adult BM when transplanted at the same 
doses, maintaining 1.8-2.4% chimerism over ~32 weeks. We boosted transplanted mice 
postnatally with adult BM cells following busulfan conditioning. Engraftment was maintained 
at >1% only in recipients which were chimeric prior to boosting. IUHCT-treated non-chimeras 
and non-IUHCT mice showed micro- or no chimerism. Additional fludarabine treatment 
produced higher chimerism than busulfan alone. Engraftment was more effective following 
higher starting chimerism prior to boosting and in heterozygotes. Chimeric heterozygotes 
expressed 2.2-15.1% donor cells with eventual decline at 24 weeks (vs. <1% in non-
chimeras) and demonstrated improved haematological indices and smaller spleens 
compared to untreated heterozygotes. Intravenous delivery of GLOBE lentiviral-vector 
expressing HBB (human β-globin) resulted in vector concentration of 0.001-0.6 copies/cell. 
Most haematological indices were higher in treated than untreated heterozygotes including 
haemoglobin and mean corpuscular volume, though still lower than in wild-types. Thus both 
direct IUGT and IUHCT strategies can be used to achieve haematological improvement but 
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require further dose optimisation. IUHCT will be useful combined with postnatal 
transplantation to further enhance engraftment.  
Word count 250 
Key words Thalassaemia, intrauterine gene therapy, haemopoietic stem cell, intrauterine cell 
therapy, postnatal transplantation, fludarabine, HbbTh3/+ mouse, GLOBE vector. 
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Introduction 
The haemoglobinopathies are the most prevalent monogenetic disorders generating 1 
substantial medical and socioeconomic burden worldwide [1]. α-thalassaemia major is 2 
perinatally lethal and necessitates effective intrauterine intervention to avoid the 3 
complications of chronic severe hypoxia evident in transfusion-dependent survivors [2]. β-4 
thalassaemia major and sickle cell disease (SCD) demand substantial resources to prevent 5 
permanent organ failure [3]. Much of the disease burden arises from suboptimal treatment 6 
[4]. Curative postnatal allogeneic haemopoietic stem cell transplantation (HSCT) is available 7 
to one third of individuals with thalassaemia and requires bone marrow (BM) conditioning, 8 
risking well-documented complications [5]. Due to the projected expansion of at-risk 9 
populations there is an urgent need to formulate an early-intervention strategy that is 10 
effective and safe [6]. While α-thalassaemia major clearly requires an intrauterine remedy 11 
given the early fatality, fetal treatment of β-haemoglobinopathies is debatable as clinical 12 
manifestations only arise in infancy. However, acknowledging the risks of conventional 13 
treatment and the therapeutic advantage of youth, a strong argument can be made for fetal 14 
therapy in which the goal is reduction of disease burden [7, 8]. Potential benefits of 15 
intrauterine cell and gene therapy for these and other genetic disorders are widely described 16 
[9, 10]. Notable advantages of intrauterine haemopoietic cell transplantation (IUHCT) include 17 
the high donor cell:fetal mass ratio (dose-dependent response), immune-naïveté (donor cell 18 
tolerance) and diminished host competition for available haematopoietic niches [11]. 19 
Advantages of intrauterine gene transfer (IUGT) include the greater transducibility of fetal 20 
target cells and lower risk of immune-mediated clearance [10]. Potential correction of these 21 
conditions well before irreversible end-organ damage and avoidance of treatment-related 22 
morbidity underscores the expectation that intrauterine therapies will benefit both α- and β-23 
thalassaemia major, similar to treatment of congenital immunodeficiency syndromes and 24 
osteogenesis imperfecta [2, 12].  25 
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Despite its promise, IUHCT has been largely disappointing in most monogenetic conditions 26 
due to host immune and competitive barriers [13]. In mice, achieving sustained engraftment 27 
within a competent host immune system requires a minimum initial donor cell chimerism of 28 
1.8% [14]. Although higher engraftment has been achieved in animal models, therapeutic 29 
engraftment has been difficult to replicate in humans [15]. The unique micro-environment in 30 
the BM of thalassaemic individuals and the lack of a competitive advantage for donor cells 31 
suggests that a strategy more complex than a single IUHCT may be needed to reach 32 
therapeutic effect [16], such as transplanting high-dose maternal donor cells within the 33 
optimal gestational window and T-cell manipulation of the donor inoculum [17-19]. The 34 
alternative approach of in-vivo intrauterine gene transfer (IUGT) has been utilised in a murine 35 
α-thalassaemia model to achieve erythroid-specific α-globin expression lasting seven months 36 
[20]. In adult individuals with β-thalassaemia ex-vivo gene therapy has met with reasonable 37 
success; this approach is impractical in the fetus as it necessitates multiple invasive 38 
procedures [21]. IUGT may present an effective way to target fetal haematopoietic 39 
progenitors and has demonstrated success in treating other models of monogenetic disease 40 
[9]. HIV-1-based integrating lentiviral vectors (LV) are valuable in the treatment of 41 
haemoglobinopathies as they transduce quiescent haematopoietic stem cells (HSC), are less 42 
mutagenic than γ-oncoretroviruses and are becoming safer and more efficient for clinical use 43 
through improved design [21, 22]. To study and compare the outcomes of IUHCT and IUGT 44 
we utilised the HbbTh3/+ murine model in which surviving heterozygotes clinically represent 45 
severe β-thalassaemia intermedia while non-surviving homozygotes represent α-46 
thalassaemia major [23]. We examined the additive effect of postnatal transplantation 47 
following IUHCT and the efficacy of a single intrauterine injection of LV-MA821 (GLOBE) 48 
expressing a human β -globin (HBB) transgene [24].  49 
50 
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Materials and Methods 51 
Animal experiments 52 
Animal experiments were performed at the National University of Singapore (NUS), an 53 
AAALAC-accredited institution and followed guidelines described in the NIH Guide for the 54 
Care and Use of Laboratory Animals under the NUS Institutional Animal Care and Use 55 
Committee (IACUC) and the Office of Safety, Health and Environment (OSHE). B6.129P2-56 
Hbb-b1tm1UncHbb-b2tm1Unc/J mice (“HbbTh3/+”) and C57BL/6.CD45.1 (“B6”) were purchased 57 
from the Jackson Laboratories (Bar Harbor, ME) while Crl:CD1[ICR] females (“CD1”) were 58 
purchased from Charles River Laboratories (Wilmington, MA). C57BL/6-Tg[UBC-59 
GFP]30Scha/J.CD45.2 mice (“B6-GFP”) used as BM donors at 6-8 weeks were kindly 60 
donated by F. Ginhoux (Singapore Immunology Network, A*STAR, Singapore). We mated 61 
HbbTh3/+ males and HbbTh3/+ or B6 females for IUHCT performed intraperitoneally (IP) at 62 
E13-14, and HbbTh3/+ males and CD1 females for IUGT performed intravenously (IV) at 63 
E15-16. The day of plug observation was designated E0.5 (Supplemental Figure S1). 64 
Animals were sacrificed with inhalational CO2 or cervical dislocation for terminal harvests.  65 
Murine BM and fetal liver donor cell preparation  66 
BM cells and fetal liver (FL) donor cells were harvested from long bones of B6-GFP adults 67 
and E13-14 fetuses respectively. Cells collected in phosphate buffered saline (PBS; Gibco, 68 
Grand Island, NY, USA) containing 2mM ethylenediaminetetraacetic acid (EDTA, Sigma) at 69 
pH7.2 were processed into single-cell suspensions by passage through a 22-gauge needle, 70 
and centrifuged over 15ml of Ficoll-Histopaque 1077 (Sigma, USA) as described [25]. 71 
Mononuclear cells (MNC) were harvested from the interphase layer, washed in PBS, frozen 72 
and thawed in batches for IUHCT. Donor MNC were consistently >95% for GFP, ~70% 73 
negative for lineage markers (Lin-) and ~20-40% cKit and Sca1 positive, thus we used the 74 
whole MNC component without further enrichment to prevent potential loss of proliferating 75 
long-term repopulating HSC [26]. Viable MNC confirmed by trypan blue exclusion were T-cell 76 
depleted with FITC anti-mouse CD3-antibody, incubated with anti-FITC microbeads and 77 
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passaged through magnetic columns (Mouse CD3 Depletion Kit, Miltenyi Biotec, 78 
Singapore)[27]. Flow cytometry (FACS) confirmed a CD3+ component <0.5% of the final 79 
inoculum. Final cell concentrations were prepared according to live cell counts. CD26 80 
inhibition was performed with Diprotin A (Peptides International, Louisville, KY) prior to 81 
transplantation as described [28]. 82 
Lentiviral vector preparation  83 
GLOBE is a self-inactivating HIV-based LV encoding mini-HBB, linked to the HS2 and HS3 84 
elements of the HBB locus control region (LCR) [29]. LV stocks were generated by triple 85 
plasmid co-transfection of human embryonic kidney 293 (HEK293T) cells, using the 86 
packaging plasmid pCMVδR8.2 (9.75µg), the envelope plasmid pMD2.G (5.25µg) and 87 
transfer vector plasmid MA821 (15µg for transfection of a single 75cm2 flask) with a Calcium 88 
Phosphate Transfection Kit (Invitrogen, USA) as described [24, 30]. Briefly, we collected 89 
medium after 48 and 72 hours of transfection, concentrated vector particles by centrifugation 90 
(90,000g, 140 minutes, 40C), re-suspended pellets in sterile PBS with 1% bovine serum 91 
albumin and quantified titers by quantitative PCR (qPCR), using forward primer 5’-92 
TGAAAGCGAAAGGGAAACCA-3’ and reverse primer 5’-CCGTGCGCGCTTCAG- 3’, 93 
specific for the rev-response element (RRE) region [24].  94 
Intrauterine cell and vector administration  95 
All procedures were performed under isoflurane anaesthesia with dams given caprofen and 96 
enrofloxacin (at 0.1ml/10g body-weight) before midline laparotomies at which uterine horns 97 
exteriorized and injections administered with a 34-gauge Hamilton needle (Bonaduz, 98 
Switzerland) under the stereomicroscope. For IUHCT, murine BM GFP+ MNC (B6-GFP) 99 
were delivered IP in 10µL, at 2E+6 (low-dose, BMLD) or 5E+6 (high-dose, BMHD) cells/fetus. 100 
FL cells were injected IP at 2E+6 (FLLD) or 5E+6 (FLHD) cells/fetus. For IUGT a 20 µL 101 
suspension of GLOBE was administered IV via the vitelline peripheral yolk sac vessel at 102 
5E+6 transforming units (TU)/fetus [31, 32]. We endeavoured to inject all fetuses in each 103 
litter. The maternal abdomen was closed in two layers with absorbable polyglactin sutures. 104 
Dams recovered in clean warm cages and were kept in a quiet environment until they 105 
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littered. Pups were cross-fostered on co-parturient CD1 dams and genotyped (Supplemental 106 
data). Postnatal transplantations were performed via tail-vein injections following IP busulfan 107 
and with CD26 inhibition of adult BM donor cells [25, 28]; some animals also received IV 108 
fludarabine (Supplemental data).  109 
Surveillance and terminal harvest  110 
Blood samples collected via tail venipuncture were analysed for haemoglobin concentration 111 
(Hb), RBC counts, red cell indices and haematocrit (Hct) on HemaVet 950 automated blood 112 
cell analyzer (Drew Scientific, FL). Blood smears were stained with May–Grunwald/Giemsa. 113 
B6-GFP chimerism was assessed in the peripheral blood MNC of HET and WT recipients for 114 
24-32 weeks (w) of age by FACS for GFP and anti-mouse CD45.2 (conjugated to APC) and 115 
calculated as the percentage of GFP+ cells as a fraction of the total CD45.2 mononuclear 116 
cell population (all antibodies from Biolegend, Singapore). We analysed 50,000 to 100,000 117 
events for FACS. Vector biodistribution was assessed with 15ng genomic DNA serially 118 
extracted from nucleated peripheral blood cells and from other tissues at terminal harvest 119 
[31], in a qPCR using standard late reverse transcript (LRT) primers specific for the rev-120 
responsive element (RRE) region complementary to the vector backbone (forward primer 5’-121 
TGAAAGCGAAAGGGAAACCA-3’, reverse primer 5’-CCGTGCGCGCTTCAG-3’) with mouse 122 
ACTB as a loading control (forward primer 5’- GGTGCTAAGAAGGCTGTT-3’ and reverse 123 
primer 5’- GGATACCTCTCTTGCTCTG-3’) for estimation of average vector copy number 124 
(VCN) per cell.  125 
Statistical Analysis 126 
Parametric data are shown as mean ± standard deviation (SD) and were analyzed using 127 
one-way or two-way analysis of variance and unpaired t tests. Non-parametric data were 128 
analyzed using the Mann–Whitney Test. p≤0.05 was considered significant. Analyses were 129 
performed on GraphPad Prism ver.6.04 (La Jolla, CA).  130 
131 
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Results 132 
IUHCT with adult BM and FL donor cells  133 
To investigate the ability to rescue HbbTh3/+ and β0/β0 homozygotes we performed IP-134 
IUHCT with coisogenic B6-GFP cells and compared outcomes with FL cells at the same 135 
doses (Figure 1A). There were no surviving homozygotes. BMHD (n=10) demonstrated higher 136 
overall chimerism than BMLD (n=14) over 20w (1.3±0.9% vs. 0.6±0.5%, p=0.06) with 137 
chimerism ranging from 0.2-3.1% and 0.01-1.2% respectively. Differences between both 138 
groups were significant at 8w (BMHD 3.1±2.5 vs. 0.7±0.9 BMLD, p=0.001, Figure 1B). HET 139 
mice (n=9) showed higher chimerism compared to WT (n=6) following BMLD treatment 140 
(1.6±0.4% vs. 0.7±0.2, p=0.05); differences were significant at 20w (1.1% vs. 0.01%, 141 
p=0.006). HET maintained low chimerism of 0.9-4.1% until 24w while WT (initially 0.2-1.7%) 142 
lost engraftment by 20w (Figure 1C). As all surviving FL-IUHCT pups were WT, comparisons 143 
were made with BM-IUHCT WT mice injected in the same batch. FLLD (n=8) demonstrated 144 
chimerism of 0.9-4.4% (mean 1.8±1.3%, undetectable at 32w) while FLHD (n=8) showed 0.2-145 
4.7% chimerism (mean 2.4±1.5%, >1% at 32w); both groups maintained stable low 146 
chimerism until ~28-32w (Figure 1D). Mean chimerism was similar between the groups 147 
(2.4±1.5% FLHD vs. 1.8±1.2% FLLD, p=0.45). Higher chimerism resulted from FLHD compared 148 
to BMHD (2.4±1.5% vs. 1.2±0.5%, p=0.07); this difference was significant at 3w (4.3% vs. 149 
0.6%, p<0.05). FLLD showed similar overall chimerism to BMHD (1.8±1.3% vs. 1.2±0.6%, 150 
p=0.07) and higher chimerism than BMLD (1.8±1.3% vs. 0.7±0.5%, p=0.03).  151 
Postnatal transplantation with busulfan and fludarabine  152 
To counter early engraftment loss we boosted chimeric (>1%) mice postnatally with B6-GFP 153 
adult BM cells with single and multiple doses. BMHD and BMLD IUHCT recipients were given 154 
5E+6 cells IV at 5w (Figure 2A). BMLD produced chimerism of 2.0±0.9% (range 0.7-3.2%) 155 
similar to BMHD of 2.7±1.2% (1.3-5.0%, p=0.3). Both lost chimerism after 16-20w. Unboosted 156 
BMHD controls maintained 1.6±0.9% chimerism; differences between BMHD and controls were 157 
significant at 16w (1.3% vs. 0.3%, p=0.04). We performed multiple postnatal boosts to 158 
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maintain engraftment in BMLD chimeras (>1%, n=8) and non-chimeras (n=8), using 5-30E+6 159 
BM cells at 5, 10 and 15 postnatal weeks (Figure 2B). Post-boost chimerism was higher in 160 
chimeras compared to boosted non-chimeras (2.1±0.9 vs 0.1±0.1, p<0.001); individual time-161 
point differences were significant at 24w (4.1 vs 0.001%, p=0.03). Chimerism was 162 
maintained >1% and mostly>1.8% until 24 weeks. Non-IUHCT boosted mice (n=3) showed 163 
no postnatal chimerism. To assess the effect of transient immuno-suppression on sustained 164 
engraftment a preliminary assessment of fludarabine use was performed on BMLD mice 165 
which showed <1% chimerism post-IUHCT (Figure 2C). Mice were given 10E+6 BM cells at 166 
4w and 8E+6 cells at 6w (doses varied due to donor-cell availability). Fludarabine treatment 167 
(n=2) in addition to busulfan maintained chimerism at 0.2-0.7% after the second boost and 168 
resulted in higher donor-cell levels than busulfan alone (n=2, 0.4±0.2% vs. 0.1±0.1% 169 
respectively, p=0.3). No differences in chimerism were observed between IUHCT mice with 170 
and without post-natal boost in this group. Non-IUHCT treated pups transplanted postnatally 171 
showed no chimerism.  172 
We then boosted BMHD mice with fludarabine and busulfan twice at 4w and 10w to determine 173 
engraftment duration, each dose being 10E+6 cells (Figure 2D). IUHCT-treated chimeras 174 
(n=4) demonstrated 5.2±8.1% donor-cell levels prior to postnatal boost which peaked at 175 
15.1±25.1% and decreased to 4.9±8.4% after the first boost. The second produced a further 176 
increase to 9.6±16.2% before eventual wastage to <1% by 24 weeks. Non-chimeras (n=4) 177 
did not show improvement after either boost, with levels remaining at 0.1-0.4%, significantly 178 
lower than chimeras (0.2±0.1% vs. 6.7±4.6, p<0.0001, Figure 2D, inset). The highest 179 
expressers maintained levels of 2.3-52.4% and 1.0-14.7% and were HET by genotype. Both 180 
had smaller (though still enlarged) spleens compared to non-chimeras and untreated HET 181 
and ongoing haemolysis (Figure 2E,F). Treated HET showed increased MCV and reduced 182 
RDW compared with untreated HET (47.3±6.2fL vs. 35.4±4.9fL, and 34.3±4.3% vs. 183 
44.1±8.6% respectively, p<0.05), approaching the levels of WT (Figure 2G). Although treated 184 
HET still had lower Hb than WT there were no differences in MCV and MCH (49.9±2.6fL vs. 185 
47.3±6.2fL and 16.2±1.6pg vs. 13.6±2.9pg respectively, p>0.05).  186 
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IUGT with GLOBE  187 
We generated GLOBE concentrates containing ~2.6E+8TU/mL (Figure 3A). We injected 188 
5E+6TU of GLOBE IV into hybrid fetuses at E15-16 to assess in-vivo IUGT (Figure 3B). 189 
Vector biodistribution and haematological indices in GLOBE-injected mice and controls were 190 
monitored from 3-24w postpartum. There was no difference in MNC VCN in peripheral blood 191 
between HET (n=13, 0.1±0.2copies/cell) and WT (n=20, 0.2±0.1copies/cell, p=0.5) 192 
detectable until 20w post-IUGT. Monthly VCN ranged from 0.001-0.4 copies/cell in both 193 
groups (Figure 3C). Terminal analyses at 20w (n=3) showed no VCN differences between 194 
treated HET and WT in blood (0.06±0.05 vs. 0.18±0.09copies/cell), BM (0.01±0.01 vs. 195 
0.006±0.003copies/cell) and liver (0.001±0.001 vs. 0.005±0.004copies/cell) respectively 196 
(Figure 3D). Most haematological indices were higher in treated than in untreated HET: Hb 197 
(11.0±1.1g% vs. 9.3±1.4g%, p=0.04), MCV (48.3±3.5fL vs. 35.4±4.9fL, p=0.004) and RBC 198 
(7.7±0.9E+6/µL vs. 5.3±0.6E+6/µL, p=0.001), with a trend towards normal RDW (35.8±1.6% 199 
vs. 44.1±8.6%, p=0.1). Significant time-point differences between treated and untreated HET 200 
are indicated in Figure 3E. Haematological values remained statistically lower in treated HET 201 
compared to WT. 202 
203 
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Discussion 204 
We demonstrate partial improvement in the HbbTh3/+ mouse model with two clinically-205 
applicable strategies of low-dose in-vivo GLOBE-IUGT and IUHCT with postnatal boost with  206 
fludarabine, which achieved preferential engraftment in chimeras and heterozygotes over 207 
non-chimeras and wild-type offspring. While we did not achieve full phenotypic correction 208 
with either, we observed that most haematological indices in treated HET improved 209 
compared to non-treated HET, an effect marginally superior with IUGT despite the low VCN. 210 
IUHCT has long been limited by low-level chimerism in animal models due to steadfast 211 
engraftment barriers [33, 34], which have been challenged though manipulation of donor 212 
cells and recipient BM microenvironment.  213 
We performed IP-IUHCT with a dose of 2-5E+6 cells/fetus, similar to studies which have 214 
demonstrated dose-dependent chimerism of 0-7.5% (2E+4-2E+6cells/fetus IP), 10-20% 215 
(2.5E+6cells/fetus IH) and 5-20% (5E+6cells/fetus IP) with eventual long-term decline in WT 216 
mice [14, 35, 36], and stable chimerism of 0.5-1.7% in the CLAD canine model (IP, 2-5E+8 217 
CD34+cells/kg) [37]. In thalassaemia and SCD mice however, single allogeneic IP-IUHCT of 218 
5E+6 adult BM cells/pup resulted in lower chimerism of 1.1-4.1% over 10 months [33, 38]. 219 
These data are informative of the expected chimerism resulting from a starting IP/IH dose of 220 
2-5E+6 cells of ~5-20% in WT mice and ~1-4% in haemoglobinopathy models. Our donor-221 
cell chimerism of 2.3-4.9% at 3 postnatal weeks is comparable but the duration of 222 
engraftment was much shorter without postnatal boost. We administered ~4-10E+9 cells/kg 223 
at E14-16 (weights 0.5-0.7g), two log-folds higher than the recommended dose for optimal 224 
engraftment in postnatal umbilical cord blood (UCB) transplantations of ~4E+7 nucleated 225 
cells/kg, albeit with conditioning therapy [39]. The engraftment shortfall in our model reflects 226 
other physiological such as the lack of space and immune rejection, and technical barriers. 227 
Although IV injections allow delivery of a much higher cell dose (20-30E+6 vs. 5E+6 IP) with 228 
significantly higher short-term engraftment [40], there is little difference in long-term 229 
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engraftment between IV-IUHCT (20E+6 cells/fetus, 5-10% at 6 months [28, 40]) and IH or IP-230 
IUHCT (2.5-5E+6 cells/fetus, 5-20% [14, 35, 36]). IV-IUHCT at this early gestation is 231 
technically demanding and IP or IH injections are more reproducible, an important 232 
consideration for clinical application particularly when fetuses are targeted in early gestation 233 
[41]. Congenic IUHCT produces lower, but ultimately more stable, chimerism compared to 234 
the allogenic IUHCT in which the majority of engrafted cells are lost through immunological 235 
clearance [13, 35]. Our congenic transplantation showed rapid engraftment loss over 24 236 
weeks following initial chimerism of 2.3-4.9% at a comparable dose of 5E+6 cells/fetus; this 237 
shortfall in long-term stability is probably related to other intrinsic barriers in this disease 238 
model. Human FL cells have demonstrated distinct competitive advantages over adult BM 239 
and UCB HSC in transplantation, and a postnatal dose of 1E+6 resulted in partial 240 
erythropoietic correction in a neonatal thalassaemic murine model [42, 43]. The chimerism of 241 
1.8-2.4% we attained with FL-IUHCT were at the lower range reported by Hayashi et al of 2-242 
10% with 1E+6 FL cells/fetus which improved haematological indices transiently [33]. There 243 
are practical and ethical challenges of using FL in the presence of suitable alternatives such 244 
as maternal BM and UCB HSC [17, 44]. FL-IUHCT in human recipients and large animals 245 
has, in contrast to murine and ovine studies [33, 45], consistently produced low and transient 246 
chimerism [11, 15], and similarly poor engraftment in postnatal recipients [46]. CD34 harvest 247 
from FL or UCB is limited, although the typical yield will be sufficient for fetal transplantation 248 
[47]. Maternal BM is readily available for repeat transplantations and produced 22% 249 
chimerism following intracardiac delivery of 2.5-5.2E+10 cells/kg at 0.67G in canines [17], 250 
though our own experience with maternal BM-IUHCT in macaques using ~1E+9 cells/kg in 251 
early gestation has produced low macro- and microchimerism (manuscript in preparation).  252 
Transfusion independence in successfully transplanted patients with thalassaemia requires 253 
10-20% engraftment of normal HSC, facilitated by aggressive myeloablation aimed at 254 
maximal reduction of BM cells, as persistent engraftment depends heavily on minimising 255 
residual host cells [48, 49]. With IUHCT in the thalassaemic mouse, without the benefit of BM 256 
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clearance a single dose of 5E+6 adult BM donor cells/fetus resulted in short-term chimerism 257 
in our study (2.3-4.9%) similar to other β-thalassaemia murine studies (1.1-4.1%) using the 258 
same dose [33, 38]. Chronic changes in the BM microenvironment impair the capacity of 259 
transduced HSC to engraft and mature in the long-term [16]. The thalassaemic niche is 260 
under constant physiological stress from ineffective erythropoiesis and compensatory 261 
expansion of erythroid progenitors; osteoporosis and osteopenia may add further strain [50]. 262 
These events alter the macromolecular structure and biochemical content of BM cells 263 
affecting interactions between HSC and other BM cells which may contribute to lower 264 
engraftment efficacy [51, 52]. IUHCT-treated β-thalassaemia mice illustrate this with five-fold 265 
lower chimerism than WT pups treated with the same donor-cell dose [33, 36, 38], as does 266 
IUHCT in human fetuses prenatally-diagnosed with major haemoglobinopathies [15].  267 
Thus IUHCT may be most useful as part of a multi-pronged approach to induce donor-268 
specific tolerance in-utero prior to postnatal transplantation to maintain therapeutic 269 
engraftment. These combined approaches have employed booster doses of 30E+6cells/pup 270 
which resulted in >1% chimerism mainly due to the competitive advantage conferred by BM 271 
clearance or CD26 inhibition preceding transplantation [25, 28, 38, 53]. High-dose total body 272 
irradiation (TBI) improved the initial ~2% chimerism in thalassaemic mice to ~70% (vs. ~15% 273 
without TBI), sufficient to correct splenomegaly and erythropoiesis [38, 53]. Enhanced 274 
postnatal engraftment was similarly achieved with CD26 inhibition or pre-transplantation 275 
high-dose busulfan [25, 28]. We used IP-IUHCT of 5E+6 cells/fetus to create donor-cell 276 
tolerance, followed by busulfan and fludarabine to create space and maintain peripheral 277 
tolerance to postnatal boost. Fludarabine is well tolerated when combined with busulfan in 278 
reduced-toxicity conditioning regimens for allogenic HSCT for a range of haematological 279 
diseases [54]. We also used a much lower booster dose of 10E+6cells/pup at 4 weeks 280 
(~20g) and would have delivered 5E+8 cells/kg, similar to the optimal nucleated-cell dose for 281 
postnatal BM transplantation in juveniles of 4E+8 cells/kg [55]. We were unable to 282 
consistently provide sufficient donor cells for doses of 30E+6 cells/pup. Thus we increased 283 
Page 15 of 28
Dighe et al. Intrauterine therapy in a thalassaemia mouse model 
 
16 
 
postnatal immune-suppression while keeping the booster dose low to determine our ability to 284 
maintain chimerism >1.8%, the threshold associated with sustained engraftment and 285 
tolerance in mice [14]. We observed a lower chimerism of 3-20% among boosted chimeric 286 
animals. Treated HET still showed improved MCV and RDW and smaller spleens compared 287 
to untreated HET; though Hb was still lower than WT mice, the differences in MCV and MCH 288 
between treated HET and WT mice were now insignificant, similar to other studies [33]. As 289 
perinatal TBI carries significant toxicity [56],  interventions to overcome host competition 290 
have been reviewed including early high-dose transplantation before endogenous BM 291 
population [17] and host BM clearance with anti-c-kit receptor antibodies [57]. However, to 292 
achieve IUHCT before BM population in a human fetus, prenatal diagnosis of a major 293 
haemoglobinopathy should be completed before 16 weeks’ gestation as fetal BM 294 
erythropoiesis begins at 16-18 weeks (0.4-0.45G) [58]. While possible, we anticipate that the 295 
majority of at-risk patients will diagnosed after this gestation and some degree of BM 296 
clearance will still be necessary to boost engraftment. Alternatively, intrauterine manipulation 297 
of the fetal BM may disrupt its stability and increase the risk of teratogenicity.  298 
GLOBE-IUGT significantly improved haematological indices in treated HET mice, though 299 
with incomplete phenotype correction. This is the second demonstration of a therapeutic 300 
effect with direct LV-IUGT in thalassaemic mice [20]. Ex-vivo gene transfer (GT) in juveniles 301 
and adults with β-haemoglobinopathies demonstrate varying degrees of success from 302 
modest haemoglobin improvement to complete transfusion-independence [21]. 303 
Haemopoietin correction and oncogenic risk both increase with higher VCN [59-61]. 304 
Erythropoeitic correction is anticipated with LV-mediated HSC transduction of ~10-20% and 305 
severe murine β-thalassemia intermedia was cured with a VCN of 1-2.5 LV copies/HSC [59-306 
61]. We used a LV dose of 5E+6 TU/mL, 1-2 log-folds lower than doses in published studies, 307 
to keep VCN to <1 copy/nucleated blood cell which carries the lowest risk of integration 308 
mutagenesis [60-62]. At this low VCN we still observed a significant improvement in Hb, 309 
MCV and RBC counts and a trend towards a lower RDW in treated compared to untreated 310 
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HET. Although these values were significantly different from WT mice, they suggest the utility 311 
of in-vivo LV-IUGT once dosage is optimised. Improved design and enhanced therapeutic 312 
efficacy expand the utility of LV-mediated HSC transduction for affected individuals for whom 313 
curative HSCT is unavailable or prohibitively expensive [63]. Of particular concern is the 314 
increased integration potential near growth-control regions due to the open structure of fetal 315 
chromatin [64]. GLOBE has a low capacity for genotoxicity because of low-frequency 316 
integration, transgene expression restricted to differentiated erythropoietic cells, and low 317 
incidence of aberrant gene-splicing in human cell lines [24, 61], and this profile is unlikely to 318 
change with in-utero administration. 319 
While both direct LV-IUGT and IUHCT are potential options for fetal therapy, consensus 320 
opinion is that IUHCT is more suitable for clinical trials presently due to unanswered 321 
questions regarding IUGT safety; however recent promising clinical trials in children may 322 
soon change this perspective [65, 66]. It may be argued that intrauterine therapy should be 323 
reserved for historically lethal α-thalassaemia major; with the considerable limitations of 324 
conventional therapy, fetal intervention will still benefit the chronic β-haemoglobinopathies. 325 
IUHCT will be valuable in a multi-pronged strategy aimed at donor-cell tolerance through 326 
fetal chimerism and enhanced engraftment through postnatal therapy.  327 
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Figure Legends  
Figure 1. Murine adult bone marrow (BM) and fetal liver (FL) mononuclear cells 
transplanted into HbbTh3 murine fetuses. (A) BMLD (2E+6) or BMHD (5E+6) B6-GFP 
donor cells were administered to E13-14 pups (HbbTh3/+ males x HbbTh3/+ or B6 females). 
(B) This produced overall chimerism of 0.6±0.5% vs. 1.3±0.9% respectively (p=0.06), 
significant at 8 weeks (0.7±0.9% vs. 3.1±2.5%, p=0.001). (C) HET mice had higher 
chimerism compared to WT after BMLD treatment (1.6±0.4% vs. 0.7±0.2, p=0.05) and 
maintained low chimerism of 0.9-4.1% until 24 weeks while WT chimerism (0.2-1.7%) was 
lost by 20 weeks (D) FLLD demonstrated 0.9-4.4% chimerism until 32 weeks; FLHD showed 
0.2-4.7% chimerism (>1% at 32w). Mean chimerism was similar between the groups 
(2.4±1.5% FLHD vs. 1.8±1.2% FLLD, p=0.45). There were no surviving HET FL-IUHCT pups. 
*p<0.05.  
Figure 2. Postnatal transplantation to boost chimerism following intrauterine 
transplantation. Adult BM mononuclear cells were postnatally transplanted into chimeric 
and non-chimeric IUHCT recipients to boost engraftment. Black arrows indicate time-points 
of postnatal transplantation. (A) BMHD and BMLD IUHCT recipients were given 5E+6 cells IV 
at 5 weeks. BMLD produced 2.0±0.9% chimerism (range 0.7-3.2%) and BMHD produced 
2.7±1.2% chimerism (1.3-5.0%, p=0.3). Both lost chimerism after 16-20 weeks. Unboosted 
BMHD controls maintained 1.6±0.9% chimerism. (B) Multiple boosts to BMLD chimeras and 
non-chimeras with 5-30E+6 BM cells produced higher donor-cell levels in chimeras (2.1±0.9 
vs 0.1±0.1, p<0.001) which was maintained mostly >1.8% until 24 weeks. Non-IUHCT 
boosted mice (n=3) showed no postnatal chimerism. (C) Transient immuno-suppression was 
produced with IV fludarabine in BMLD recipients (<1% chimerism post-IUHCT) before 
postnatal boosts of 10E+6 BM cells at 4 weeks and 8E+6 cells at 6 weeks. Fludarabine-
treated mice maintained chimerism at 0.2-0.7% after the second boost and had higher 
donor-cell levels than non-fludarabine treated controls (0.4±0.2% vs. 0.1±0.1% respectively, 
p=0.3). IUHCT mice with and without post-natal boost and non-IUHCT treated pups 
transplanted postnatally showed minimal or no chimerism. (D) BMHD mice were treated with 
fludarabine and 10E+6 cells twice at 4 and 10 weeks. Chimeras showed increased donor-
cell levels after each boost (overall chimerism 6.7±4.6%) before eventual wastage to <1% by 
24 weeks. Non-chimeras did not show improvement after either boost (inset). Two treated 
chimeras maintained levels of 2.3-52.4% and 1.0-14.7% and were HET by genotype. Both 
had ongoing haemolysis (E) and smaller (though still enlarged) spleens (F) compared to non-
chimeras. (G) Treated HET showed increased MCV and reduced RDW compared with 
untreated HET (47.3±6.2fL vs. 35.4±4.9fL, and 34.3±4.3% vs. 44.1±8.6% respectively, 
p<0.05), approaching the levels of WT. Treated HET had lower Hb than WT but there were 
no differences in MCV and MCH (49.9±2.6fL vs. 47.3±6.2fL and 16.2±1.6pg vs. 13.6±2.9pg 
respectively, p>0.05). *p<0.05. 
Figure 3: Intrauterine injection of lentiviral vectors expressing murine B globin in 
HbbTh3 murine fetuses. To examine the effectiveness of IUGT we administered i.v. 
injections of GLOBE (A), a lentiviral vector constructed to express the human β-globin mini-
gene in the erythropoietic lineage, driven by the β-locus control region (β-LCR, comprising 
HS2/HS3). (B) Pups were injected at E15-16 with a LV dose of 5E+6 TU in 20µl via the 
perivitelline vein. (C) VCN in treated HET and WT mice were similar all time-points (means 
0.1 and 0.2 copies/cell respectively, p=0.5); both groups demonstrated an increasing VCN 
that peaked at 8 weeks (mean ~0.4 ±1.4 copies/cell) and was not detectable (ND) by 24 
weeks. (D) There were no differences in low-level VCN in blood, BM and liver at 20 weeks. 
(E) Haematological parameters showed an overall improvement in treated vs. untreated 
HET: Hb (11.0±1.1g% vs. 9.3±1.4g%, p=0.04), MCV (48.3±3.5fL vs. 35.4±4.9fL, p=0.004) 
and RBC (7.7±0.9x106/µL vs. 5.3±0.6 x106/µL, p=0.001) with reduced RDW (35.8±1.6% 
treated vs. 44.1±8.6% untreated, p=0.1). *p<0.05.  
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